최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0390799 (2006-03-27) |
등록번호 | US-8187620 (2012-05-29) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 2 인용 특허 : 446 |
The invention relates generally to a medical device, such as an intravascular stent, for delivering a therapeutic agent to the body tissue of a patient, and a method for making such a medical device. More particularly, the invention pertains to a medical device having a metal oxide or metal material
The invention relates generally to a medical device, such as an intravascular stent, for delivering a therapeutic agent to the body tissue of a patient, and a method for making such a medical device. More particularly, the invention pertains to a medical device having a metal oxide or metal material with a plurality of pores therein disposed on the surface of the medical device and a polymer disposed on the metal oxide or metal material. The invention also relates to medical devices having a surface and an outer region comprising a metal oxide or metal material having a plurality of pores therein and a polymer disposed on the metal oxide or metal material.
1. An implantable medical device comprising: (a) a surface;(b) a coating disposed on the surface comprising: (i) a first material comprising a first transition metal oxide material in the form of a layer having a plurality of pores therein disposed on at least a portion of the surface, wherein a fir
1. An implantable medical device comprising: (a) a surface;(b) a coating disposed on the surface comprising: (i) a first material comprising a first transition metal oxide material in the form of a layer having a plurality of pores therein disposed on at least a portion of the surface, wherein a first therapeutic agent is disposed in at least some of the pores of the first transition metal oxide material;(ii) a first polymer in the form of a layer disposed on at least a portion of the first transition metal oxide material, wherein the first polymer has a plurality of pores therein; and(c) an outer region adjacent to the surface, wherein the outer region comprises a second material comprising a second transition metal oxide material different from the first transition metal oxide material, the second transition metal oxide material having a plurality of pores therein, and a second therapeutic agent disposed in at least some of the pores of the second transition metal oxide material; wherein the first and second therapeutic agents are the same or different. 2. The device of claim 1 further comprising an inner region adjacent to the outer region, wherein the inner region is substantially non-porous. 3. The device of claim 1 further comprising a second polymer disposed in at least some of the pores of the first transition metal oxide material. 4. The device of claim 1, wherein the first polymer comprises ethylene-vinylacetate copolymers, polymethacrylates, styrene-isobutylene copolymers and polylactic acids. 5. The device of claim 1, wherein the first and second transition metal oxide materials each independently comprises tantalum oxide, titanium oxide, iridium oxide, niobium oxide, zirconium oxide, tungsten oxide, or rhodium oxide. 6. The device of claim 1, wherein the pores in the first transition_metal oxide material have an average width of between about 1 nm and about 10 μm. 7. The device of claim 1, wherein the first and second therapeutic agents each independently comprises an anti-restenosis agent, anti-thrombogenic agent, anti-angiogenesis agent, anti-proliferative agent, antibiotic agent, growth factor, immunosuppressant or radiochemical. 8. The device of claim 1, wherein the first therapeutic agent, the second therapeutic agent, or both, comprises an anti-restenosis agent. 9. The device of claim 1, wherein the first therapeutic agent, the second therapeutic agent, or both, comprises paclitaxel. 10. The device of claim 1, wherein the first therapeutic agent, the second therapeutic agent, or both, comprises sirolimus, tacrolimus, pimecrolimus or everolimus. 11. The device of claim 1, wherein the first polymer comprises polyethylene-co-vinyl acetate, poly(n-butyl methacrylate), poly(styrene-b-isobutylene-b-styrene) and polylactic-glycolic acid. 12. The device of claim 1, wherein the first polymer comprises a third therapeutic agent dispersed in the pores of the first polymer, and wherein the first therapeutic agent and the third therapeutic agent are the same. 13. An implantable medical device comprising: (a) an inner region having at least two surfaces, wherein the inner region is substantially non-porous;(b) an outer region adjacent to each surface of the inner region, wherein the outer region comprises a second material comprising a second transition metal oxide material in the form of a layer having a plurality of pores therein, and a second therapeutic agent disposed in at least some of the pores in the second transition metal oxide material;(c) a coating disposed on each of the outer regions comprising: (i) a first material comprising a first transition metal oxide material different from the second transition metal oxide material, the first transition metal oxide material in the form of a layer having a plurality of pores therein disposed on at least a portion of the surface, wherein a first therapeutic agent is disposed in at least some of the pores of the first transition metal oxide material; and(ii) a first polymer in the form of a layer disposed on at least a portion of the first transition metal oxide material, wherein the first polymer has a plurality of pores therein. 14. The device of claim 1, wherein the first polymer comprises a second therapeutic agent included in the pores of the first polymer. 15. The device of claim 14, wherein the second therapeutic agent is the same as the first therapeutic agent. 16. The device of claim 14, wherein the second therapeutic agent is different from the first therapeutic agent.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.